Related Experiment Video
Updated: Aug 8, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Use of angiotensin type II receptor blockers as a potential strategy for chronic heart failure]
Atsushi Nakano1, Masahumi Kitakaze
1Division of Cardiovascular Unit, National Cardiovascular Center.
Abstract:
Angiotensin II is one of the most important key molecules for cardiac remodeling and apoptosis, culminating in heart failure. Therefore, angiotensin II receptor blockers (ARBs) have been expected to improve the mortality and morbidity in patients with heart failure more effectively strict elimination of the effects of angiotensin II compared with angiotensin-converting-enzyme inhibitors (ACEI). Here, we summarize the current clinical outcomes obtained from large scale trials using ARBs as a strategy of the treatment of heart failure, and discuss the pharmacological differences between ARB and ACEI and the future direction of the treatment of heart failure.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure V: Medical Management
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure II: Pathophysiology